| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ... Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018 | 1055 | 2018 |
| Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Presented in part at the 42nd annual meeting of the American … G Del Poeta, A Venditti, MI Del Principe, L Maurillo, F Buccisano, ... Blood, The Journal of the American Society of Hematology 101 (6), 2125-2131, 2003 | 455 | 2003 |
| Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management R Stasi, ML Evangelista, E Stipa, F Buccisano, A Venditti, S Amadori Thrombosis and haemostasis 99 (01), 4-13, 2008 | 415 | 2008 |
| Clinical significance of CD38 expression in chronic lymphocytic leukemia G Del Poeta, L Maurillo, A Venditti, F Buccisano, AM Epiceno, G Capelli, ... Blood, The Journal of the American Society of Hematology 98 (9), 2633-2639, 2001 | 396 | 2001 |
| Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st Annual Meeting of the American Society … A Venditti, F Buccisano, G Del Poeta, L Maurillo, A Tamburini, C Cox, ... Blood, The Journal of the American Society of Hematology 96 (12), 3948-3952, 2000 | 345 | 2000 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 339 | 2021 |
| Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia F Buccisano, L Maurillo, MI Del Principe, G Del Poeta, G Sconocchia, ... Blood, The Journal of the American Society of Hematology 119 (2), 332-341, 2012 | 334 | 2012 |
| Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia V Gattei, P Bulian, MI Del Principe, A Zucchetto, L Maurillo, F Buccisano, ... Blood, The Journal of the American Society of Hematology 111 (2), 865-873, 2008 | 317 | 2008 |
| Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis SA Buckley, BL Wood, M Othus, CS Hourigan, C Ustun, MA Linden, ... haematologica 102 (5), 865, 2017 | 255 | 2017 |
| The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ... haematologica 92 (9), 1173-1179, 2007 | 242 | 2007 |
| Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia MI Del Principe, G Del Poeta, F Buccisano, L Maurillo, A Venditti, ... Blood 108 (3), 853-861, 2006 | 240 | 2006 |
| Toward optimization of postremission therapy for residual disease–positive patients with acute myeloid leukemia L Maurillo, F Buccisano, MI Del Principe, G Del Poeta, A Spagnoli, ... Journal of clinical oncology 26 (30), 4944-4951, 2008 | 195 | 2008 |
| Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial M Marchetti, G Barosi, F Balestri, G Viarengo, S Gentili, S Barulli, ... Journal of clinical oncology 22 (3), 424-431, 2004 | 187 | 2004 |
| Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 … EN Oliva, C Alati, V Santini, A Poloni, A Molteni, P Niscola, F Salvi, ... The Lancet Haematology 4 (3), e127-e136, 2017 | 180 | 2017 |
| Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult … F Buccisano, L Maurillo, A Spagnoli, MI Del Principe, D Fraboni, ... Blood, The Journal of the American Society of Hematology 116 (13), 2295-2303, 2010 | 177 | 2010 |
| Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia G Del Poeta, R Stasi, G Aronica, A Venditti, MC Cox, A Bruno, ... | 173 | 1996 |
| Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic … MT Voso, S Fenu, R Latagliata, F Buccisano, A Piciocchi, MA Aloe-Spiriti, ... J Clin Oncol 31 (21), 2671-2677, 2013 | 172 | 2013 |
| GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia A Venditti, A Piciocchi, A Candoni, L Melillo, V Calafiore, R Cairoli, ... Blood, The Journal of the American Society of Hematology 134 (12), 935-945, 2019 | 167 | 2019 |
| The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia F Buccisano, L Maurillo, V Gattei, G Del Poeta, MI Del Principe, MC Cox, ... Leukemia 20 (10), 1783-1789, 2006 | 166 | 2006 |
| Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program L Maurillo, A Venditti, A Spagnoli, G Gaidano, D Ferrero, E Oliva, ... Cancer 118 (4), 1014-1022, 2012 | 153 | 2012 |
Adriano VendittiProfessore Ordinario di EmatologiaVerified email at uniroma2.it
